NCT07905352
A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)
Timeframe: 52 Weeks
Secondary (14)
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog13)
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
15-item Geriatric Depression Scale (GDS-15)
Mini-Mental State Examination (MMSE)
Plasma p-tau181
Show 9 moreShow less
Plasma p-tau217
Plasma p-tau231
Plasma Aβ42
Plasma Aβ40
Plasma Aβ42/Aβ40 Ratio
Plasma Glial Fibrillary Acidic Protein (GFAP)
Plasma Neurofilament Light Chain (NfL)
Brain Aβ-PET Centiloid (CL)
Adverse Events (AEs) and Serious Adverse Events (SAE
Arms and interventions
Simenafil Hydrochloride TabletsExperimental
2.5 mg/5 mg /10 mg, administered orally once daily for 52consecutive weeks
Placebo TabletPlacebo comparator
Administered orally once daily for 52 consecutive weeks
Drugs: Simenafil Hydrochloride Tablets 2.5 mg, Simenafil Hydrochloride Tablets 5 mg, Simenafil Hydrochloride Tablets 10 mg, Placebo Tablets
Sites
1 site in 1 country
- Xuanwu Hospital ,Capital Medical UniversityBeijing, Beijing Municipality, China